According to him, "At present, we have published preclinical trials based on mice, and the results of these studies have shown that by increasing the expression of three longevity genes, FGF21, STGF R2, and Klotho, we have improved or even completely reversed 4 aging-related diseases in mice: obesity, type II diabetes, heart failure, and kidney failure, and the key is that these 4 diseases can be intervened simultaneously by a single gene**, and not only that, we are now expanding our research to prove this gene** It can also intervene for 5 aging-related diseases at the same time. ”
At this stage, there are 3 pipelines under development at the level of aging genes. Among them, the lead**RJB-01 targets the STGF R2 and FGF21 genes and is used for cardiovascular, metabolic, and renal diseases. At present, the preclinical trials of the pipeline for pet dogs have been completed, and it is expected to apply for new drug clinical research approval (IND) next year and enter phase 1 clinical trials to commercialize it. The second line, RJB-02, targets the STGF R2 and Klotho genes for osteoarthritis. Both it and the third pipeline are currently in preclinical studies.
Preventing aging diseases requires more than just anti-agingIn 2013, an article published in Cell listed nine major mechanisms of aging that are currently known, including: genomic instability, epigenetic changes, telomere wear, loss of protein homeostasis, metabolic dysregulation, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and abnormal cell-to-cell communication.
Several studies have confirmed that intracellular NAD+ decreases with age, with consequences including downregulation of mitochondrial energy production, oxidative stress, DNA damage, cognitive impairment, etc., resulting in a decline in the function of various tissues and organs in the body.
NAD+ is a coenzyme that exists in the body, which catalyzes many kinds of cellular metabolic functions through cellular redox reactions to maintain normal substance metabolism, fatty acid metabolism, energy synthesis, cellular DNA repair and other functions.
Based on the findings of this pathway, researchers believe that increasing NAD+ levels may slow or even reverse all aspects of aging in the body and may delay age-related disease progression. This perspective has increased interest in NAD+ supplementation.
Globally, a number of preclinical studies and clinical studies have been carried out by several research institutions such as Keio University and Harvard University in Japan, and widely supported by D**id Sinclair, a tenured professor in the Department of Genetics at Harvard Medical School. Domestically, studies from the National Clinical Research Center for Geriatrics in China have also shown that the supplement can alleviate age-related physiological decline and pulmonary fibrosis in mice.
In March last year, the company launched its first "Leyuetai" anti-aging series products. Focusing on the research related to the NAD+ pathway, it reconstructs the logic of action of the anti-aging ingredient fisetin and the substance, and jointly constructs the NAD+ internal circulation pathway through the combination of NAD+ multi-source precursors, the regulation of NAD+ NADH ratio, the discharge of metabolites, and the activation of the circulating salvage pathway, and contains multiple anti-inflammatory and antioxidant synergists screened by the high-throughput platform. At present, this series of products has been launched on the Jingdong platform and has received tens of thousands of praises. "Ingredients alone don't work well. Previously, most products on the market only saw a single active ingredient, and there was a lack of systematic research and formulation optimization. "The AI-optimized complex formula "Joy Tec" can increase the bioavailability of NAD+ supplements by more than 180%.
Based on the AI technology platform "Transforming scientific problems into industrial problems".At present, based on the pharmacological information knowledge graph of known substances such as FDA, OTC, GRAS, etc., as well as R&D and clinical data, and with the superior technology of many leading AI pharmaceutical companies at home and abroad, the company has established an artificial intelligence-based anti-aging substance screening platform PassTM. The platform will provide support in drug delivery, drug formulation, ingredient ratio, etc., which will not only improve the effectiveness and stability of the substance, but also improve R&D efficiency and reduce R&D costs.
Is aging a disease?In the past decade, people's understanding of aging has deepened, and the relevant academic system has become more systematic and mature. With anti-aging science as the seed, many anti-aging star candidates such as rapamycin, metformin, and proanthocyanidins have contributed to a sunrise industry. In January of this year, Altos Labs was officially announced with $3 billion in funding, becoming an "instant unicorn". On the one hand, the company has made a name for itself with the participation of well-known scientists such as Shinya Yamanaka, Juan Carlos Izpisua Belmonte, Wolf Reik, etc., and on the other hand, it has attracted the support of Amazon founder Jeff Bezos and DST Global founder Yuri Milner. The company will focus on exploring the deep biology of cell reprogramming to restore cellular health and vitality.